tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Syntara Limited Secures A$5.6 Million R&D Tax Incentive
Company AnnouncementsSyntara Limited Secures A$5.6 Million R&D Tax Incentive
6d ago
Pharmaxis Ltd Highlights Strategic Initiatives at Healthcare Conference
PremiumCompany Announcements
Pharmaxis Ltd Highlights Strategic Initiatives at Healthcare Conference
21d ago
Pharmaxis Receives FDA Guidance on Amsulostat’s Clinical Pathway
PremiumCompany Announcements
Pharmaxis Receives FDA Guidance on Amsulostat’s Clinical Pathway
29d ago
Syntara Limited Enhances Corporate Governance Framework
PremiumCompany Announcements
Syntara Limited Enhances Corporate Governance Framework
1M ago
Syntara Limited Affirms Governance Compliance for FY2025
PremiumCompany Announcements
Syntara Limited Affirms Governance Compliance for FY2025
1M ago
Pharmaxis Ltd Releases Annual Financial Report for 2025
PremiumCompany AnnouncementsPharmaxis Ltd Releases Annual Financial Report for 2025
1M ago
Syntara Limited Reports Improved Financial Performance for 2025
Premium
Company Announcements
Syntara Limited Reports Improved Financial Performance for 2025
1M ago
Syntara Limited to Quote New Securities on ASX
Premium
Company Announcements
Syntara Limited to Quote New Securities on ASX
1M ago
Pharmaxis Ltd Discusses Syntara’s Future Prospects and Risks
PremiumCompany Announcements
Pharmaxis Ltd Discusses Syntara’s Future Prospects and Risks
1M ago
Syntara Limited to Host Investor Webinar on Amsulostat Development
PremiumCompany Announcements
Syntara Limited to Host Investor Webinar on Amsulostat Development
2M ago
Syntara Receives FDA Guidance on Amsulostat Development for Myelofibrosis
PremiumCompany Announcements
Syntara Receives FDA Guidance on Amsulostat Development for Myelofibrosis
2M ago
Syntara Limited Announces New Securities Issuance
PremiumCompany Announcements
Syntara Limited Announces New Securities Issuance
2M ago
Syntara Limited Resumes Trading on ASX
PremiumCompany AnnouncementsSyntara Limited Resumes Trading on ASX
2M ago
Syntara Limited Proposes CEO Performance Rights Issuance
Premium
Company Announcements
Syntara Limited Proposes CEO Performance Rights Issuance
2M ago
Pharmaxis Ltd Releases Quarterly Update on Strategic Developments
Premium
Company Announcements
Pharmaxis Ltd Releases Quarterly Update on Strategic Developments
2M ago
Syntara Limited Schedules Investor Webinar Amidst Quarterly Update
PremiumCompany Announcements
Syntara Limited Schedules Investor Webinar Amidst Quarterly Update
2M ago
Syntara Limited Reports Quarterly Cash Flow
PremiumCompany Announcements
Syntara Limited Reports Quarterly Cash Flow
2M ago
Syntara Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Syntara Limited Announces Quotation of New Securities on ASX
2M ago
Syntara Limited Advances Drug Pipeline with Promising Amsulostat Developments
PremiumCompany Announcements
Syntara Limited Advances Drug Pipeline with Promising Amsulostat Developments
2M ago
Syntara Begins Phase 1a/b Trial for Anti-Scarring Drug SNT-9465
PremiumCompany AnnouncementsSyntara Begins Phase 1a/b Trial for Anti-Scarring Drug SNT-9465
2M ago
Syntara Limited Launches AZALOX Clinical Trial for Blood Cancer Treatment
Premium
Company Announcements
Syntara Limited Launches AZALOX Clinical Trial for Blood Cancer Treatment
2M ago
Syntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment Prospects
Premium
Company Announcements
Syntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment Prospects
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >